AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether…
AI stocks rebound, and why J&J’s earnings guidance cut is not cause for concern
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
What to know about testosterone replacement therapy
US Secretary of Defense Pete Hegseth speaks during a press briefing at the Pentagon in Washington, DC, on…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
Trump tariffs fall, but trade war impacts linger
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off…
Biotech is resistant to AI disruption. Josh Brown likes these two stocks in the industry
(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo…
AI robots may outnumber workers in few decades: former Citi exec
AI robots will exceed the working population within a few decades as more firms adopt AI agents and…
15 drugs added to Medicare price negotiations
Boxes of the drug trulicity, made by Eli Lilly and Company, sit on a counter at a pharmacy…
Johnson & Johnson halts mid-stage trial of experimental eczema drug
Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg |…
The healthcare sector is having its market moment. How to find the Best Stocks in the space
(This is The Best Stocks in the Market , brought to you by Josh Brown and Sean Russo…
Eli Lilly, Merck, Gilead and AbbVie earnings preview
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday,…
Trump pharmaceutical tariff threat lessens after Pfizer deal
U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with…